I am an associate professor at The Ohio State University Moritz College of Law and a faculty member of Ohio State’s Drug Enforcement and Policy Center. I am also a member of the Cancer Control Program at the OSUCCC – James, where my research focuses on FDA law and policy.

Cancer-relevant areas of interest include the intersection of state/local and FDA regulation; First Amendment constraints on government regulation of tobacco and drug industry speech; ethical and legal questions regarding cancer patients’ non-trial pre-approval access to investigational drugs; cannabis and psychedelic decriminalization and regulation; and questions regarding the scope of FDA jurisdiction (e.g., which things the FDA can regulate, and which things are properly considered drugs vs. tobacco products).

My work has been published in peer-reviewed scientific journals, including New England Journal of Medicine, JAMA, Science, Journal of Clinical Oncology, JAMA Oncology, and EMBO Molecular Medicine, as well as in leading legal journals. I am also a coauthor of the 5th edition of Food and Drug Law: Cases and Materials (with Peter Barton Hutt, the late Richard A. Merrill, Lewis A. Grossman, Nathan Cortez, and Erika Lietzan).

I currently serve on the Food and Drug Law Institute’s Board of Directors and on the International Society of Cell & Gene Therapy’s Committee on the Ethics of Cell and Gene Therapy, chairing its subcommittee on expanded access. Before my academic career, I was an associate chief counsel at the FDA.